S&P 500   4,966.57 (-0.89%)
DOW   37,949.61 (+0.46%)
QQQ   414.40 (-2.13%)
AAPL   165.07 (-1.18%)
MSFT   399.32 (-1.22%)
META   481.12 (-4.12%)
GOOGL   153.90 (-1.35%)
AMZN   174.24 (-2.78%)
TSLA   146.99 (-1.96%)
NVDA   769.04 (-9.17%)
AMD   146.04 (-5.83%)
NIO   3.81 (-4.75%)
BABA   69.08 (+0.29%)
T   16.48 (+0.92%)
F   12.09 (+0.25%)
MU   106.18 (-5.14%)
GE   148.36 (-2.99%)
CGC   7.99 (+2.04%)
DIS   112.17 (-0.23%)
AMC   3.21 (+9.93%)
PFE   25.96 (+2.24%)
PYPL   61.86 (-0.39%)
XOM   119.87 (+1.14%)
S&P 500   4,966.57 (-0.89%)
DOW   37,949.61 (+0.46%)
QQQ   414.40 (-2.13%)
AAPL   165.07 (-1.18%)
MSFT   399.32 (-1.22%)
META   481.12 (-4.12%)
GOOGL   153.90 (-1.35%)
AMZN   174.24 (-2.78%)
TSLA   146.99 (-1.96%)
NVDA   769.04 (-9.17%)
AMD   146.04 (-5.83%)
NIO   3.81 (-4.75%)
BABA   69.08 (+0.29%)
T   16.48 (+0.92%)
F   12.09 (+0.25%)
MU   106.18 (-5.14%)
GE   148.36 (-2.99%)
CGC   7.99 (+2.04%)
DIS   112.17 (-0.23%)
AMC   3.21 (+9.93%)
PFE   25.96 (+2.24%)
PYPL   61.86 (-0.39%)
XOM   119.87 (+1.14%)
S&P 500   4,966.57 (-0.89%)
DOW   37,949.61 (+0.46%)
QQQ   414.40 (-2.13%)
AAPL   165.07 (-1.18%)
MSFT   399.32 (-1.22%)
META   481.12 (-4.12%)
GOOGL   153.90 (-1.35%)
AMZN   174.24 (-2.78%)
TSLA   146.99 (-1.96%)
NVDA   769.04 (-9.17%)
AMD   146.04 (-5.83%)
NIO   3.81 (-4.75%)
BABA   69.08 (+0.29%)
T   16.48 (+0.92%)
F   12.09 (+0.25%)
MU   106.18 (-5.14%)
GE   148.36 (-2.99%)
CGC   7.99 (+2.04%)
DIS   112.17 (-0.23%)
AMC   3.21 (+9.93%)
PFE   25.96 (+2.24%)
PYPL   61.86 (-0.39%)
XOM   119.87 (+1.14%)
S&P 500   4,966.57 (-0.89%)
DOW   37,949.61 (+0.46%)
QQQ   414.40 (-2.13%)
AAPL   165.07 (-1.18%)
MSFT   399.32 (-1.22%)
META   481.12 (-4.12%)
GOOGL   153.90 (-1.35%)
AMZN   174.24 (-2.78%)
TSLA   146.99 (-1.96%)
NVDA   769.04 (-9.17%)
AMD   146.04 (-5.83%)
NIO   3.81 (-4.75%)
BABA   69.08 (+0.29%)
T   16.48 (+0.92%)
F   12.09 (+0.25%)
MU   106.18 (-5.14%)
GE   148.36 (-2.99%)
CGC   7.99 (+2.04%)
DIS   112.17 (-0.23%)
AMC   3.21 (+9.93%)
PFE   25.96 (+2.24%)
PYPL   61.86 (-0.39%)
XOM   119.87 (+1.14%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$165.99
+0.8%
$175.59
$130.96
$182.89
$293.91B0.585.60 million shs3.21 million shs
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$107.17
+1.8%
$114.28
$89.67
$121.64
$185.96B0.745.69 million shs4.89 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$125.80
+0.5%
$126.17
$99.14
$133.10
$318.66B0.388.25 million shs4.88 million shs
Novartis AG stock logo
NVS
Novartis
$94.22
+1.8%
$98.22
$92.19
$108.78
$199.71B0.541.49 million shs1.67 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.96
+2.2%
$27.14
$25.23
$40.37
$147.00B0.6142.22 million shs24.07 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
+0.26%-1.71%-8.35%-0.07%+2.14%
Abbott Laboratories stock logo
ABT
Abbott Laboratories
-0.59%-5.52%-6.94%-8.26%-6.25%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-0.14%-0.75%+2.44%+5.30%+9.68%
Novartis AG stock logo
NVS
Novartis
-0.56%-1.88%-3.88%-14.47%-5.56%
Pfizer Inc. stock logo
PFE
Pfizer
-0.08%-3.61%-8.06%-10.27%-36.92%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbbVie Inc. stock logo
ABBV
AbbVie
4.9081 of 5 stars
2.45.04.23.93.02.52.5
Abbott Laboratories stock logo
ABT
Abbott Laboratories
4.9943 of 5 stars
3.45.04.24.53.12.52.5
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
4.7432 of 5 stars
2.35.03.34.13.92.51.3
Novartis AG stock logo
NVS
Novartis
2.2259 of 5 stars
2.13.02.50.01.80.02.5
Pfizer Inc. stock logo
PFE
Pfizer
4.9902 of 5 stars
3.25.04.24.82.51.73.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.77
Moderate Buy$177.436.89% Upside
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.75
Moderate Buy$121.3113.19% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.58
Moderate Buy$131.254.33% Upside
Novartis AG stock logo
NVS
Novartis
2.25
Hold$114.0020.99% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.35
Hold$36.8842.05% Upside

Current Analyst Ratings

Latest PFE, MRK, NVS, ABT, and ABBV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/18/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$128.00 ➝ $125.00
4/18/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$135.00
4/15/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
4/8/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$140.00 ➝ $143.00
4/5/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$135.00
4/4/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$120.00 ➝ $125.00
4/3/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$126.00 ➝ $128.00
4/1/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
3/28/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$139.00 ➝ $142.00
3/27/2024
AbbVie Inc. stock logo
ABBV
AbbVie
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$185.00 ➝ $195.00
3/27/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$135.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$54.32B5.41$15.98 per share10.39$5.78 per share28.72
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$40.11B4.64$6.44 per share16.65$22.36 per share4.79
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$60.12B5.30$3.05 per share41.21$14.85 per share8.47
Novartis AG stock logo
NVS
Novartis
$45.44B4.39$10.84 per share8.69$22.06 per share4.27
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.51$3.04 per share8.54$15.81 per share1.64

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.86B$2.7360.8013.672.118.95%162.28%14.62%4/26/2024 (Confirmed)
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$5.72B$3.2133.3920.852.5513.96%20.32%10.59%7/18/2024 (Estimated)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$365M$0.14898.5712.801.630.61%9.33%3.61%4/25/2024 (Confirmed)
Novartis AG stock logo
NVS
Novartis
$14.85B$7.1813.1211.821.4529.83%29.90%12.97%4/23/2024 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B$0.3672.119.371.153.62%10.88%4.91%5/1/2024 (Confirmed)

Latest PFE, MRK, NVS, ABT, and ABBV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024N/A
Pfizer Inc. stock logo
PFE
Pfizer
$0.57N/A-$0.57N/AN/AN/A  
4/26/2024N/A
AbbVie Inc. stock logo
ABBV
AbbVie
$2.20N/A-$2.20N/AN/AN/A  
4/25/2024N/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.12N/A-$2.12N/AN/AN/A  
4/17/2024Q1 24
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$0.96$0.98+$0.02$1.26$9.88 billion$9.96 billion    
2/2/202412/31/2023
AbbVie Inc. stock logo
ABBV
AbbVie
$2.76$2.79+$0.03$5.12$14.02 billion$14.30 billion    
2/1/2024Q4 2023
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-$0.09$0.03+$0.12$0.54$14.49 billion$14.63 billion    
1/30/202412/31/2023
Novartis AG stock logo
NVS
Novartis
$1.64$1.53-$0.11-$1.08$11.69 billion$11.42 billion    
1/30/202412/31/2023
Pfizer Inc. stock logo
PFE
Pfizer
-$0.19$0.10+$0.29$0.80$14.37 billion$14.25 billion    
1/24/202412/31/2023
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.19$1.19N/A$1.47$10.19 billion$10.24 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.203.74%+7.84%227.11%52 Years
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.202.05%+12.31%68.54%53 Years
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.082.45%+6.08%2,200.00%13 Years
Novartis AG stock logo
NVS
Novartis
$2.432.58%+4.26%33.84%4 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.686.47%+2.57%466.67%15 Years

Latest PFE, MRK, NVS, ABT, and ABBV Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/15/2024
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.553.54%4/12/20244/15/20245/15/2024
2/16/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
quarterly$0.551.9%4/12/20244/15/20245/15/2024
1/23/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.772.6%3/14/20243/15/20244/5/2024
3/1/2024
Novartis AG stock logo
NVS
Novartis
annual$3.77723.1%3/7/20243/8/20243/7/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
5.02
0.87
0.76
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.35
1.64
1.16
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.89
1.25
1.00
Novartis AG stock logo
NVS
Novartis
0.39
1.15
0.93
Pfizer Inc. stock logo
PFE
Pfizer
0.69
0.91
0.69

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Novartis AG stock logo
NVS
Novartis
13.12%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.25%
Abbott Laboratories stock logo
ABT
Abbott Laboratories
1.10%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.20%
Novartis AG stock logo
NVS
Novartis
0.01%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
50,0001.77 billion1.77 billionOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
114,0001.74 billion1.72 billionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
72,0002.53 billion2.53 billionOptionable
Novartis AG stock logo
NVS
Novartis
76,0572.12 billion2.12 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.66 billion5.66 billionOptionable

PFE, MRK, NVS, ABT, and ABBV Headlines

SourceHeadline
ProSource360 wins opportunity to partner with Pfizer through its Diverse OnDemand MarketplaceProSource360 wins opportunity to partner with Pfizer through its Diverse OnDemand Marketplace
finance.yahoo.com - April 19 at 2:53 PM
Pfizer (NYSE:PFE) Trading 0.9% Higher Pfizer (NYSE:PFE) Trading 0.9% Higher
marketbeat.com - April 19 at 12:25 PM
HTLF Bank Buys Shares of 31,103 Pfizer Inc. (NYSE:PFE)HTLF Bank Buys Shares of 31,103 Pfizer Inc. (NYSE:PFE)
marketbeat.com - April 19 at 11:54 AM
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending StockHere is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
zacks.com - April 19 at 10:05 AM
6 Left For Dead Blue Chip Dividend Stocks Could Rally Big This Summer6 Left For Dead Blue Chip Dividend Stocks Could Rally Big This Summer
247wallst.com - April 19 at 9:41 AM
6 Left For Dead Blue Chip Dividend Stocks Could Rally Big This Summer6 Left For Dead Blue Chip Dividend Stocks Could Rally Big This Summer
247wallst.com - April 19 at 9:41 AM
Unveiling Pfizers Potent Cocktail: Key Drivers Of Free Cash Flow GrowthUnveiling Pfizer's Potent Cocktail: Key Drivers Of Free Cash Flow Growth
seekingalpha.com - April 19 at 7:03 AM
Pfizer (NYSE:PFE) Hits New 1-Year Low at $25.26Pfizer (NYSE:PFE) Hits New 1-Year Low at $25.26
marketbeat.com - April 18 at 4:55 PM
Xponance Inc. Grows Position in Pfizer Inc. (NYSE:PFE)Xponance Inc. Grows Position in Pfizer Inc. (NYSE:PFE)
marketbeat.com - April 18 at 4:41 PM
Is Pfizer Stock A Sell As Shares Hit A 9-Year Low Amid The Search For Its Next Big Break?Is Pfizer Stock A Sell As Shares Hit A 9-Year Low Amid The Search For Its Next Big Break?
investors.com - April 18 at 1:01 PM
If Youd Invested $1,000 in Pfizer 5 Years Ago, Heres How Much Youd Have TodayIf You'd Invested $1,000 in Pfizer 5 Years Ago, Here's How Much You'd Have Today
fool.com - April 18 at 9:15 AM
Pfizer exec to join well-resourced venture capital firmPfizer exec to join well-resourced venture capital firm
thepharmaletter.com - April 18 at 9:10 AM
The 3 Most Overlooked Stocks Set for a Triple-Digit ComebackThe 3 Most Overlooked Stocks Set for a Triple-Digit Comeback
investorplace.com - April 17 at 5:48 PM
Pfizer-Connect Biopharma deal for anti-inflammatory agent endsPfizer-Connect Biopharma deal for anti-inflammatory agent ends
msn.com - April 17 at 2:42 PM
Pfizer Inc. (NYSE:PFE) Shares Acquired by KLCM Advisors Inc.Pfizer Inc. (NYSE:PFE) Shares Acquired by KLCM Advisors Inc.
marketbeat.com - April 17 at 1:39 PM
Pfizer (NYSE:PFE) Trading Down 0.8%Pfizer (NYSE:PFE) Trading Down 0.8%
marketbeat.com - April 17 at 12:42 PM
Connect Biopharma uncouples from Pfizer by scrapping long-standing eczema pactConnect Biopharma uncouples from Pfizer by scrapping long-standing eczema pact
fiercebiotech.com - April 17 at 9:42 AM
Pfizers academic-partnered R&D unit is scrapped as part of cost-cutting measuresPfizer's academic-partnered R&D unit is scrapped as part of cost-cutting measures
fiercebiotech.com - April 17 at 9:42 AM
HealthInvest Partners AB Acquires Shares of 42,820 Pfizer Inc. (NYSE:PFE)HealthInvest Partners AB Acquires Shares of 42,820 Pfizer Inc. (NYSE:PFE)
marketbeat.com - April 16 at 6:50 PM
Pfizers Doldrums, Just A Bad Case Of COVID-19?Pfizer's Doldrums, Just A Bad Case Of COVID-19?
seekingalpha.com - April 16 at 2:34 PM
Pfizer (NYSE:PFE) Stock Price Down 0.2%Pfizer (NYSE:PFE) Stock Price Down 0.2%
marketbeat.com - April 16 at 2:02 PM
Pfizers (PFE) Overweight Rating Reaffirmed at Cantor FitzgeraldPfizer's (PFE) Overweight Rating Reaffirmed at Cantor Fitzgerald
americanbankingnews.com - April 16 at 4:26 AM
Why the Market Dipped But Pfizer (PFE) Gained TodayWhy the Market Dipped But Pfizer (PFE) Gained Today
zacks.com - April 15 at 6:51 PM
Pfizer Eyeing Viking Therapeutics? A Scenario Among All The M&A TalkPfizer Eyeing Viking Therapeutics? A Scenario Among All The M&A Talk
seekingalpha.com - April 15 at 5:39 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

AbbVie logo

AbbVie

NYSE:ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Abbott Laboratories logo

Abbott Laboratories

NYSE:ABT
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Merck & Co., Inc. logo

Merck & Co., Inc.

NYSE:MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Novartis logo

Novartis

NYSE:NVS
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. It offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.